Splice modulation through exon skipping is currently the leading therapeutic strategy for the treatment of Duchenne Muscular Dystrophy (DMD) with two ASO chemistries evaluated in clinical trials for the targeting of DMD exon 45, 51, and 53: 2′-O-methyl-phosphorothioate (2′-OMe PS) and phosphorodiamidate morpholino oligomers (PMO) [6,7]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.